Cd19 And Cd20 Normal Range

Anti cd20 therapies are used to treat patients with various types of b cell lymphoma leukemia and immune disorders.

Cd19 and cd20 normal range.

It s a protein found on the surface of b cells a type of white blood cell. The distribution of these b cell subsets reference ranges based on gender is shown in table 3. Shearer wt et al. Clotted samples cannot be tested.

Cd19 is expressed on all normal mitogen stimulated and malignant b cells excluding plasma cells. 7 18 because of its ubiquity on all b cells it can function as a b cell marker and a target for immunotherapies targeting neoplastic lymphocytes. The result and loinc information listed below should not be used for electronic interface maintenance with quest diagnostics. Lymphocyte sub set normal ranges.

Since cd19 is a hallmark of b cells the protein has been used to diagnose cancers that arise from this type of cell notably b cell lymphomas. Pediatric normal range chart. The cd19 antigen plays an important role in clinical oncology. Cd20 is not expressed on hematopoietic stem cells pro b cells or normal plasma cells 1 plasmablasts and stimulated plasma cells may express cd20 2 cd20 is generally coexpressed on b cells with cd19 another b cell differentiation marker.

Cd20 is not expressed on hematopoietic stem cells pro b cells or normal plasma cells 1 plasmablasts and stimulated plasma cells may express cd20 2 cd20 is generally coexpressed on b cells with cd19 another b cell. Reference ranges for cd10 cd19 and cd20 were found to be 1 3 median 1 6 23 median 14 and 6 23 median 14 respectively table 2. Reference range s see laboratory report. Cd19 6 3 20 0 cd16 56 3 2 23 7 ratio 1 0 3 6 absolutes 18 yrs cd3 678 2504 cd3 4 414 1679 cd3 8 162 1038 cd19 96 515 cd16 56 45 523 lymphocyte subset normal range chart.

Adult normal range chart. Lymphocyte subsets in healthy children. Wbcs are stained with fluorescently labeled monoclonal antibodies to cd14 cd19 cd20 and cd45 and run on a flow cytometer and the cd19 and cd20 antigen expression are analyzed. Cd19 and cd20 monitoring.

Cd19 expression is even maintained in b lineage cells that undergo neoplastic transformation. The anti cd20 mab ofatumumab was approved by fda in october 2009 for chronic lymphocytic leukemia. Cd20 is the target of the monoclonal antibodies rituximab ocrelizumab obinutuzumab ofatumumab ibritumomab tiuxetan tositumomab and ublituximab which are all active agents in the treatment of all b cell lymphomas leukemias and b cell mediated autoimmune diseases.